---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-000263"
form_type: "8-K"
ticker: "PTIX"
cik: "0001022899"
company_name: "Protagenic Therapeutics, Inc.new"
filed_at: "2026-01-05T23:59:59+00:00"
generated_at: "2026-05-16T11:37:04.574864+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Protagenic Therapeutics receives Nasdaq delisting notice; trading to move to OTC Jan 5, 2026

## Summary
- Nasdaq determined to delist PTIX and PTIXW due to failure to meet minimum stockholders' equity (Rule 5550(b)(1)) and timely filing (Rule 5250(c)(1)).
- Trading on Nasdaq will cease at close of Jan 2, 2026; OTC trading expected to start Jan 5, 2026.
- Company has withdrawn its hearing request, making delisting final.
- Company intends to evaluate steps to regain compliance and seek relisting on Nasdaq.

## SEC filing metadata
- accession: 0001493152-26-000263
- form_type: 8-K
- ticker: PTIX
- cik: 0001022899
- company_name: Protagenic Therapeutics, Inc.new
- filed_at: 2026-01-05T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1022899/000149315226000263/0001493152-26-000263-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1022899/000149315226000263/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-000263
- JSON: https://secwatch.observer/filing/0001493152-26-000263.json
- Plain text: https://secwatch.observer/filing/0001493152-26-000263.txt

## Key facts
- Listing & Compliance Notices
  Protagenic Therapeutics, Inc.new received a nasdaq delisting notice notice regarding stockholders equity (rules 5550(b)(1)).
  - Exchange: nasdaq
  - Notice: delisting notice
  - Deficiency: stockholders equity
  - Rules: 5550(b)(1)
  source text: December 31, 2025, the Company received a letter from The Nasdaq Stock Market LLC (“Nasdaq”) stating that trading of the Company’s securities on Nasdaq would cease at the close of trading on January 2, 2026, and that Nasdaq determined to delist the Company’s securities based on the Company’s failure to satisfy Nasdaq continued listing requirements, including Nasdaq Listing Rule 5550(b)(1) (minimum stockholders’ equity) and Nasdaq Listing Rule 5250(c)(1) (timely filing of periodic reports). OTC trading is effected through registered broker-dealers, and quotation and trading information is gener
  evidence_url: https://www.sec.gov/Archives/edgar/data/1022899/000149315226000263/0001493152-26-000263-index.htm
- Listing & Compliance Notices
  Protagenic Therapeutics, Inc.new received a nasdaq delisting notice notice regarding late filing (rules 5250(c)(1)).
  - Exchange: nasdaq
  - Notice: delisting notice
  - Deficiency: late filing
  - Rules: 5250(c)(1)
  source text: December 31, 2025, the Company received a letter from The Nasdaq Stock Market LLC (“Nasdaq”) stating that trading of the Company’s securities on Nasdaq would cease at the close of trading on January 2, 2026, and that Nasdaq determined to delist the Company’s securities based on the Company’s failure to satisfy Nasdaq continued listing requirements, including Nasdaq Listing Rule 5550(b)(1) (minimum stockholders’ equity) and Nasdaq Listing Rule 5250(c)(1) (timely filing of periodic reports). OTC trading is effected through registered broker-dealers, and quotation and trading information is gener
  evidence_url: https://www.sec.gov/Archives/edgar/data/1022899/000149315226000263/0001493152-26-000263-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.